RA CAPITAL MANAGEMENT, L.P. (Kolchinsky Peter, Shah Rajeev M.) purchased $43.1M of PEPG (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. purchased 8,625,000 indirectly-held shares of PepGen Inc. (PEPG) at $5.00 ($43.12M total) on 2026-11-13. Filed jointly with RA Capital Healthcare Fund LP (Director), RA Capital Nexus Fund II, L.P. (Director), Kolchinsky Peter (Director) and Shah Rajeev M. (Director).

Original reporting
SEC EDGAR · RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Kolchinsky Peter, Shah Rajeev M.
Published Nov 17, 2026, 9:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 9:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PEPG
Bullish
medium confidence
Mentioned
$PEPG
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PEPGBullishLow
01

Why it matters

Owner buying can modestly improve sentiment, but without accompanying fundamental updates, traders typically treat it as secondary information.

02

Market read

A large disclosed purchase can attract attention, but it is unlikely to drive a sustained repricing without additional company-specific catalysts.

03

What to watch

No 10b5-1 plan is cited, but the article also provides no context on whether this is part of a larger accumulation program or a one-off adjustment.

Relevance 8/10Novelty 6/10Timing: Form 4 filed Nov. 17, covering an open-market purchase dated Nov. 13.

Background

The article is a SEC Form 4 insider transaction disclosure for PepGen Inc., reported by RA Capital Management and related directors.

Company-level read

Ticker impact

$PEPGBullishMedium confidence
Context

RA Capital Management reported an open-market purchase of 8,625,000 shares of PepGen Inc. at $5.00/share via a Form 4 filed Nov. 17.

Expected impact

Likely mild upward bias as the market interprets owner buying, though impact should be limited absent additional company-specific news.

Evidence & confidence

Form 4 insider purchases can support sentiment, but the article provides no new operational, clinical, or guidance information beyond the transaction details.

Market effects

Minimal, as this is a single-company insider transaction without sector-wide implications.

None.

None.

Counterpoint

The purchase may be routine or driven by pre-existing ownership strategy, and it does not necessarily reflect near-term upside catalysts.

Key entities

  • PepGen Inc.

    Subject of the Form 4 insider transaction; shares purchased via indirect holdings.

  • RA Capital Management, L.P.

    Reported the open-market purchase as a director and 10% owner (indirect holdings).

  • Kolchinsky Peter

    Co-reporting director listed on the joint filing.

  • Shah Rajeev M.

    Co-reporting director listed on the joint filing.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

MedAI 8/10

PepGen’s stock skyrockets on record-breaking DM1 trial data

PepGen's stock surged 132% after its Phase II trial for PGN-EDODM1 in myotonic dystrophy type 1 (DM1) met endpoints, showing high genetic modulation and functional improvements. The stock later closed at $4.61, up 92.9% from the previous close. The trial demonstrated significant splicing correction and tolerability, with data supporting continued development. PepGen expects more data in 2027.

$PEPGHighAI 8/10

PepGen Stock Doubles in One Session - Here's Why

PepGen Inc. (PEPG) stock surged 111.30% to $5.05 on Tuesday after reporting positive Phase 2 trial results for its myotonic dystrophy type 1 treatment, showing significant splicing correction and functional improvements in patients. The company reported a 46.5% average muscle splicing correction at 10 mg/kg dose, with notable gains in mobility and hand grip strength. PepGen expects to release further data in 2027.